Twist Bioscience Appoints Industry Veteran Patrick J. Finn, Ph.D., as Vice President of Sales and Marketing

Download PDF
SAN FRANCISCO, Calif. – February 2, 2015 – Twist Bioscience today named Patrick J. Finn, Ph.D., as vice president of sales and marketing. Dr. Finn, a seasoned executive with almost 20 years of life sciences industry leadership, brings extensive experience commercializing new technologies and joins Twist as the company plans to launch its synthetic biology platform services this year.
“As we prepare for the introduction of our proprietary semiconductor-based synthetic DNA offering, we are extremely pleased to welcome Paddy, with his strong track record of high- growth sales in bioreagent, B2B and custom manufacturing organizations in addition to his passion for creating strategic value within a company,” said Emily Leproust, Ph.D., chief executive officer of Twist Bioscience. “Pairing his technical background and ability to identify customer’s unmet needs with his hands-on experience in driving sales performance, we believe he is ideally suited to lead our commercial efforts at Twist.”
Dr. Finn joins Twist Bioscience from Enzymatics (recently acquired by QIAGEN), where he was vice president of sales and marketing, leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers. Prior to Enzymatics, Paddy has held positions with increasing commercial focus, including director of business development at Agilent Technologies, director of product development for Beckman Coulter Molecular Diagnostics, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International.
In addition, Dr. Finn currently serves on the scientific advisory board of Lasergen and previously served on the scientific advisory board of Enzymatics. He holds a Ph.D. in nucleic acid chemistry from Southampton University and a B.Sc. Hons in Chemistry from Heriot-Watt University.
At Twist Bioscience, our expertise is synthetic DNA. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production.
The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit